Oculus Announces FDA 501K Clearance of Microcyn Technology
PETALUMA, Calif. -- Hoji Alimi, founder and president of Oculus Innovative Sciences, today announced that the company has received its first 510K clearance from the Food and Drug Administration (FDA) to market Dermacyn Wound Care, formulated with Microcyn Technology, as a medical device for moistening, lubricating and debriding of acute and traumatic wounds and burns.
Microcyn technology is a super-oxidized, pH-neutral solution that is ready for use with no dilution or mixing, and requires no special handling or disposal. It is manufactured using a sophisticated, multi-chamber electrolysis process in which ionic species are selectively produced and isolated. This process allows for the production of a pH-neutral solution while minimizing the level of chlorine in the final product.
This FDA 510K clearance as a medical device allows the company to market its label claims and enter into negotiations with distributors for commercialization purposes. Dermacyn Wound Care, the first Microcyn technology product for human use in the United States, will be available to physicians in June 2005.
The company also received CE approval according to the European Medical Devices Directive (93/42/EEC) for Dermacyn Wound Care in November of this past year. It was certified as a Class IIb medical device for treating acute and chronic wounds (e.g., diabetic foot ulcers and burns) as part of a comprehensive wound care regimen. The Microcyn Technology received approval as a disinfectant, antiseptic and sterilant from the Mexican Ministry of Health in 2003 where the product is now widely commercialized and in use for the treatment of myriad wounds and burns. Dermacyn Wound Care also received regulatory approval this past November from the Therapeutic Product Directorate, the Canadian federal authority that regulates pharmaceutical drugs and medical devices, as a dermal wound irrigant that facilitates removal of wound debris as it cleanses and debrides.
Source: Oculus Innovative Sciences
Comprehensive Strategies in Wound Care: Insights From Madhavi Ponnapalli, MD
November 22nd 2024Madhavi Ponnapalli, MD, discusses effective wound care strategies, including debridement techniques, offloading modalities, appropriate dressing selection, compression therapy, and nutritional needs for optimal healing outcomes.
The Leapfrog Group and the Positive Effect on Hospital Hand Hygiene
November 21st 2024The Leapfrog Group enhances hospital safety by publicizing hand hygiene performance, improving patient safety outcomes, and significantly reducing health care-associated infections through transparent standards and monitoring initiatives.
Why Clinical Expertise Is the Cornerstone to Your Most Profitable Business Line
November 14th 2024Perioperative nurses bring vital skills in patient safety, infection control, and quality improvement. They enhance surgical outcomes and support health care systems during complex, high-risk procedures.
Strengthening Defenses: Integrating Infection Control With Antimicrobial Stewardship
October 11th 2024Use this handout to explain the basics of why infection prevention and control and antimicrobial stewardship are essential and how the 2 fields must have a unified approach to patient and staff safety
Blood Product Overtransfusion Is a Global Issue: Here Are 5 Reasons the Practice Must Change
October 9th 2024If a patient receives treatment or therapy that they do not need, it can cause unnecessary harm. This is true for medications, surgeries, and medical procedures, especially blood transfusions.
